NIKKEI 225
27,821.76 -462.16 (-1.63%) HANG SENG
23,309.64 -542.60 (-2.27%) CRUDE OIL
67.48 -2.47 (-3.53%) GOLD FUTURES
1,794.00 +8.80 (+0.49%) DOW
35,135.94 +236.60 (+0.68%) BTC-GBP
42,367.04 -951.50 (-2.20%)
Inventiva S.A. (0RNK.L)
| Previous close | 11.96 |
| Open | 11.66 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 11.60 - 11.66 |
| 52-week range | 11.60 - 11.66 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 144.867M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.21 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Inventiva reports 2021 Third Quarter Financial Information
Cash and cash equivalents at €105.7m as of September 30, 2021Revenues of €0.2m for the first nine months of 2021 Daix (France), Long Island City (New York, United States), November 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today reported it
- Globe Newswire
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn SchattenbergUpdate on the current NASH landscape by Prof. Nezam AfdhalUpdate on Inventiva’s Phase II clinical trial evaluating lanifibranor in patients with type 2 diabetes (T2D) and non alcoholic fatty liver disease (NAFLD) by Prof. Kenneth CusiPresentation of Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflo
- Globe Newswire
Inventiva announces participation at several conferences in November 2021
Daix (France), Long Island City (New York, United States), November 29, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in two upcoming conferences in November 2021. The event details are
